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Abstract 24 
Human chaperonin 10 (Cpn10) and chaperonin 60 (Cpn60) fulfil an essential role in 25 
mitochondrial protein folding.  Cpn10 is located in the mitochondrial matrix; however, it 26 
has also been detected in extra-mitochondrial compartments where it has demonstrated 27 
anti-inflammatory and immunoregulatory activity, suggesting a potential therapeutic value 28 
for the treatment of inflammatory and autoimmune disorders that corresponds with its 29 
recently proposed role as a resolution-associated molecular patterns (RAMPs) molecule.    30 
Ala-Cpn10, a recombinant, minimally modified Cpn10 synthesized in Escherichia coli, is 31 
formulated for use in clinical trials and pre-clinical studies with intravenous or 32 
subcutaneous administration.  Herein, we report the development of a bioprocess for the 33 
production of ~115 g of recombinant human Ala-Cpn10 from a 100 litre E. coli 34 
fermentation with >99% purity (SDS-PAGE), <0.6 EU mg-1 endotoxin, <18 pg mg-1 DNA 35 
and 3.2% molecular variants.  This bioprocess was achieved through a careful optimisation 36 
of the gene construct, the promoter system and the fermentation process. Recombinant 37 
Ala-Cpn10 produced in this process is active as a molecular chaperone indicating correct 38 
tertiary and quaternary structure and the stability profile indicates no significant changes 39 
with storage as a liquid for at least 3 years at 2-8 oC.  The results of validated 40 
characterisation assays demonstrate that purified Ala-Cpn10 produced using the optimised 41 
process reported here is suitable for its intended purpose as an investigational drug product, 42 
and this material is currently being tested in a phase II study for efficacy, safety and impact 43 
on biomarkers in subjects with mildly active Systemic Lupus Erythematosus (SLE) under 44 
US IND 116156. 45 
 46 
Keywords: Cpn10, endotoxin, immunomodulator, inflammation, RAMPs, Systemic Lupus 47 
Erythematosus (SLE). 48 
49 
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Introduction 49 
Chaperonin 10 (Cpn10) is a member of the stress or heat shock family of proteins.  This 50 
group of proteins is among the most highly conserved in nature, with respect to both 51 
structure and function.  Human Cpn10 has 100% homology with bovine, porcine and 52 
rabbit Cpn10 while rat Cpn10 differs from human by one amino acid [1].  Localized in 53 
various intracellular compartments, heat shock proteins (HSPs) have a well-defined role in 54 
protein assembly, translocation and degradation.  Cpn60 together with its co-chaperone 55 
Cpn10, reside primarily within mitochondria where they fulfil an essential role in 56 
mitochondrial protein folding [2].  Stress proteins are up-regulated in response to hypoxia, 57 
hypoglycaemia, ionising radiation and heat-shock [3, 4] and released from cells through as 58 
yet undefined mechanisms.  Once in the extracellular environment, a number of stress 59 
proteins have demonstrated autocrine, paracrine and endocrine immunological activity [5].  60 
Cpn10 has demonstrated anti-inflammatory and immunoregulatory activity and has been 61 
proposed as a member of the resolution-associated molecular patterns (RAMPs) family of 62 
molecules [6].  As a RAMP, Cpn10 is hypothesised to regulate the acute immune response 63 
with therapeutic potential to restore homeostasis in a dysregulated setting such as chronic 64 
inflammation and autoimmune disease. 65 
 66 
Cpn10 members are dome-shaped, heptameric rings comprised of identical 10 kDa 67 
subunits [7 8].  The test material described herein is Cpn10 produced in bacteria as a 68 
recombinant protein.  An N-terminus comparison of native human Cpn10 with 69 
recombinant Cpn10 reveals the substitution of two hydrogen (H) groups for a methyl (CH3) 70 
and an amino (NH3+) group in recombinant Cpn10 (Ala-Cpn10).   71 
 72 
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In vitro, recombinant Cpn10 inhibited TNF-α and IL-6 secretion from human peripheral 73 
blood mononuclear cells (PBMC) stimulated with bacterial lipopolysaccharide (LPS) [9]. 74 
Data from animal models of inflammation show that Cpn10 pre-treatment of mice 75 
significantly reduced serum concentrations of TNF-α and regulated upon activation normal 76 
T cell expressed and secreted (RANTES) while increasing serum IL-10 following sub-77 
lethal LPS administration [9].  Observations of potential immunomodulatory activity in 78 
animal models of human disease, including adjuvant arthritis [10], experimental 79 
autoimmune encephalitis [11], allogeneic skin grafting [12] , Graft-versus-host disease [9] 80 
and systemic lupus erythematosus [13] provide a rationale for clinical trials of Cpn10 81 
safety and efficacy in humans. 82 
 83 
Nine clinical studies have been completed investigating recombinant Cpn10 administration 84 
in various populations.  In the clinical studies conducted to date there appear to be no 85 
hepatic, haematologic or other obvious effects of concern.  The proof of concept studies in 86 
subjects with rheumatoid arthritis (RA) and psoriasis (PS), showed modest 87 
immunomodulatory effects and a reduction in the signs and symptoms of disease from pre-88 
treatment levels with intravenous (i.v.) Cpn10 dosing.  Cpn10 reduced production of TNF-89 
α, IL-1β and IL-6 in response to LPS stimulation of human PBMC from healthy volunteers 90 
and patients with autoimmune disease [multiple sclerosis (MS), psoriasis (PS), rheumatoid 91 
arthritis (RA)] [9 14 15].  Combined with the toxicokinetic profile generated thus far, these 92 
data confirm the safety and tolerability of Cpn10 in patients and support further 93 
investigation in subjects with systemic lupus erythematosus or other autoimmune diseases. 94 
 95 
Currently the standard of care for subjects with mild-to-moderate manifestations of SLE 96 
includes small molecule compounds such as non-steroidal anti-inflammatory drugs, 97 
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antimalarial drugs such as  hydroxychloroquine and corticosteroids such as prednisone. 98 
Patients with active disease and organ threatening lupus are usually treated with 99 
immunosuppressants (either methotrexate, leflunomide or azathioprine).   Recently 100 
approved biological agents (belimumab)  target specific cytokines, such as BLyS [B 101 
lymphocyte stimulator, also known as BAFF (B-cell activating factor)] a cytokine essential 102 
for the survival of B cells, although questions remain regarding the durability of the 103 
clincial response [16]. Thus opportunities still exist for the development of new, safe and 104 
effective treatments for SLE, including other biological therapeutics for this autoimmune 105 
disease. 106 
 107 
The production of biologics (such as proteins) in an Escherichia coli system incurs the risk 108 
of contamination with molecules known as pathogen-associated molecular patterns 109 
(PAMPs), the most well-known example being LPS.  PAMPs describe the evolutionarily 110 
conserved microbial components that are recognised by the eukaryotic host through 111 
binding to pattern-recognition receptors such as CD14 or the Toll-like receptors (TLRs) 112 
[17].  Endotoxins are pro-inflammatory and thus their presence in biologics may be toxic 113 
and result in artefactual effects on eukaryotic cells.  It is therefore critical that recombinant 114 
protein preparations have minimal impurities such as endotoxin, DNA and other 115 
microorganism-derived components.   116 
 117 
Regulatory bodies stipulate that the manufacturer of a biologic should assess and 118 
characterise both process-related impurities (i.e. host cell proteins, endotoxin, DNA etc), 119 
and the levels of product-related substances (i.e. molecular variants of the native product) 120 
(EMEA, CPMP/ICH/365/96).  The product specification sets out an acceptance criteria for 121 
impurities and product-related substances within numerical limits, and includes some detail 122 
of specific tests and analytical procedures used.  Characterisation of the product is 123 
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performed in the early stages of bioprocess development, and following subsequent 124 
changes to the bioprocess.  Apart from meeting specifications for process-related 125 
impurities, an important facet of bioprocess optimisation is minimising levels of product 126 
variant. 127 
 128 
In compliance with regulatory requirements and in order to facilitate the safe and effective 129 
testing of Cpn10 administration in patients with autoimmune disease, it was essential that a 130 
rigorous purification methodology be devised to remove process-related impurities from 131 
Cpn10.  132 
 133 
This study describes the bioprocess development, production and subsequent 134 
characterisation of recombinant human Cpn10 produced in E. coli, the first chaperone 135 
protein to enter clinical trials for treatment of disease indications associated with 136 
inflammation.   137 
 138 
Materials and Methods 139 
E. coli host strains 140 
XL1-Blue (endA1 gyrA96 (nalR) thi-1 recA1 relA1 lac glnV44 hsdR1 F'[ ::Tn10 proAB+ 141 
lacIq Δ(lacZ)M15]) (Stratagene, CA, USA).  BR067 (glnV44 (AS) rfbC1 endA1 spoT1 thi-1 142 
hsdR17 creC510 ∆ompT) is a proprietary derivative of E. coli strain MM294 (ATCC 143 
#33625) developed at Hospira, Adelaide, Australia. 144 
 145 
Cloning and expression of human Cpn10 in E. coli 146 
Initial cloning and expression of Cpn10 was as described in Somodevilla-Torres et al. 147 
(2003) [18].  Ala-Cpn10 pPL550, a heat-inducible expression plasmid encoding human 148 
Cpn10 with an additional N-terminal alanine was transformed into XL1-Blue and Cpn10 149 
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expression examined in complex media.  A master cell bank (MCB) of the XL1-Blue 150 
production clone was established at Acyte Pty Ltd, Sydney, Australia which was 151 
subsequently expanded at Hospira, Adelaide, Australia.  Synthetic genes with the 152 
appropriate flanking restriction enzyme cleavage sites were obtained from GENEART AG, 153 
Regensberg, Germany.   154 
 155 
Cpn10 expression from Hospira’s host strain BR067 and lac promoter-based expression 156 
vectors was examined following growth and induction in defined media.  A final 157 
production strain for manufacture of clinical trial material was selected on the basis of high 158 
level Cpn10 expression and concomitant low level expression of product variants.  A MCB 159 
was established from a single selected clone and a working cell bank (WCB) generated by 160 
expansion of a single MCB vial.   Both cell banks were characterised to ensure suitability 161 
for use in manufacture of clinical grade material.   162 
 163 
GMP Fermentation: XL1-Blue Cell line 164 
A MCB of XL1-Blue with the Ala-Cpn10 pPL550 plasmid was ‘pre-cultured’ overnight in 165 
Soya Peptone Broth with no antibiotic supplementation at 30 °C.  An inoculum culture was 166 
subsequently prepared for the 150 L bioreactor maintaining the above media and growth 167 
temperature parameters.  An aliquot of this inoculum was dispensed into a 150 L 168 
bioreactor in a minimal media supplemented with 1.5 g L-1 vegetable peptone and 1.0 g L-1 169 
yeast extract and no antibiotic supplementation.  The bioreactor cultivation did not require 170 
nutrient feeding and the temperature was maintained throughout the growth phase at 30 ± 2 171 
°C.  The pH was maintained at 7.0 ± 0.3 by the addition of an ammonia solution.  172 
Induction of Cpn10 was achieved by a temperature shift to 42 °C when the culture reached 173 
an optical density at 600nm (OD600nm) of 10 and further incubation at 42 ± 0.5 °C for 3 h at 174 
which time the fermentation reached a cell density of between OD600nm 20-25. 175 
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GMP Fermentation: BR067 Cell Line 176 
In brief, 100 L fed batch-fermentations for Cpn10 were carried out as follows. An 177 
inoculum culture, derived from a vial of the WCB, was grown in Vegetable Peptone Broth 178 
supplemented with kanamycin.  The inoculum was used to seed a 150 L fermenter 179 
containing 75 L chemically defined batch media (without antibiotic selection) and 180 
following overnight batch growth, the glucose based nutrient feed was supplied on demand.  181 
The cultivation temperature was maintained at 37 ± 2 °C throughout, pH maintained at 7 ± 182 
0.3 by the addition of an ammonia solution and dissolved oxygen was maintained at >30%.  183 
Induction was commenced by the addition of 6.0 g isopropyl-β-D-thiogalactopyranoside 184 
(IPTG) when the culture achieved a cell density of OD600nm ~45 and allowed to proceed for 185 
up to 5 h with final culture cell densities in excess of OD600nm 120. 186 
 187 
Cell lysis and preparation of a soluble lysate 188 
Bacterial cells were collected with a flow-through Westfalia MSB-7 centrifuge and 189 
resuspended in 25 mM Tris-HCl pH 8.0.  Following overnight storage the cells were 190 
disrupted by 3 passages through a high pressure homogeniser (APV CD30) at 7000 psi.  191 
The bacterial homogenate was processed with a flow-through Westfalia MSB-7 centrifuge 192 
and ~ 90 L of clarified, Cpn10-containing, lysate was collected and either immediately 193 
processed or stored overnight at 4 – 8 °C. 194 
 195 
Purification of Cpn10  196 
A three-step downstream process was developed for the purification of Cpn10, 197 
incorporating Big Bead Sulfopropyl-Sepharose (SP-BB) cation exchange, Q-Sepharose 198 
Fast Flow (Q-FF) anion exchange and High Performance Sepharose SP (SP-HP) cation 199 
exchange chromatography.  Chromatography was carried out using the K-Prime 40-II 200 
system (Millipore). 201 
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De-pyrogenation of chromatography columns, containers and buffers 202 
All ion-exchange (IEX) chromatography columns were depyrogenated by washing in 1 M 203 
NaOH with 100 mM NaCl and equilibrated with buffer until eluates returned to the pH of 204 
the specific buffers.  All containers used for buffer storage and receipt of column eluates in 205 
the various purification steps were depyrogenated using 1 M NaOH followed by extensive 206 
rinsing with MilliQ water (Millipore) until washings were pH neutral.  A pre-column 0.2 207 
micron filter was used for the Q-FF and SP-HP steps.   208 
 209 
Big Bead Sulfopropyl-Sepharose chromatography 210 
XL1-Blue Cell line 211 
The filtered lysate was loaded over 20-40 min onto a SP-BB cation exchange column 212 
(BPG 300/500 with 8.6 L of SP-BB Sepharose resin, GE Biosciences) pre-equilibrated 213 
with 25 mM Tris-HCl, pH 8.0 (Buffer A), at 75 cm h-1 linear flow-rate and a loading rate of 214 
up to 17 g Cpn10 L-1 of resin.  After washing with Buffer A, the captured Cpn10 was 215 
eluted with Buffer A containing 150 mM NaCl and a single fraction of 6-11 L was 216 
collected.  SDS-PAGE analysis showed the SP-BB pool to be >95% pure (data not shown).  217 
 218 
BR067 Cell Line 219 
The filtered lysate was loaded over ~110 min onto a SP-BB cation exchange column (BPG 220 
300/500 with 18 L of SP-BB Sepharose resin, GE Biosciences) pre-equilibrated with 221 
Buffer A, at 75 cm h-1 linear flow-rate and a loading rate of up to 31 g Cpn10 L-1 of resin.  222 
After washing with Buffer A, the captured Cpn10 was eluted with Buffer A containing 150 223 
mM NaCl and a single fraction of 9-16 L was collected.  SDS-PAGE analysis showed the 224 
SP-BB pool to be >95% pure.  225 
 226 
 227 
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Q-Sepharose Fast Flow chromatography 228 
The SP-BB eluate was concentrated to half the starting volume by tangential flow filtration 229 
(TFF) and diafiltered against 5 volumes of Buffer A at room temperature.  The dialysed 230 
SP-BB pool was loaded onto a BPG 200/500 column packed with 4.7 L of Q-FF anion 231 
exchange resin (GE Biosciences) pre-equilibrated in Buffer A at a linear flow-rate of 75 232 
cm h-1 and a loading rate of up to 35 g Cpn10 L-1 of resin.  The Q-FF anion exchange 233 
flowthrough containing the Cpn10 was collected.  Under the loading conditions, the 234 
majority of the E. coli cell proteins, nucleic acid and endotoxin remained bound to the 235 
matrix. 236 
 237 
Sulfopropyl-Sepharose High Performance chromatography 238 
The Q-FF flowthrough from the XL1-Blue cell line was applied to a BPG 100/500 column 239 
packed with 1.67 L of SP-HP resin (GE Biosciences), pre-equilibrated with 50 mM Tris-240 
HCl pH 7.6 (Buffer B), at ≤ 15 g Cpn10 L-1 of resin.  The Q-FF flowthrough from the 241 
BR067 cell line was applied to a BPG 140/500 column packed with 3.4 L of SP-HP resin, 242 
pre-equilibrated with Buffer B, at ≤ 15 g Cpn10 per litre of resin.  The bound Cpn10 was 243 
eluted with a 13.3 mM/column volume NaCl gradient and 0.5 L fractions were collected. 244 
The fractions were pooled according to size exclusion chromatography (SEC), HPLC and 245 
SDS-PAGE analyses.  The Cpn10 protein and NaCl ion concentrations were determined by 246 
UV Absorbance at 280 nm and the ion selective electrode (ISE) method (IDEXX 247 
Laboratories, Australia), respectively. 248 
 249 
Formulation  250 
The pooled SP-HP fractions were diluted with 50 mM Tris-HCl pH 7.6 to 5 mg/mL. Prior 251 
to dilution with 50 mM Tris-HCl pH 7.6, NaCl was dissolved in the buffer to achieve Na+ 252 
and Cl- concentrations of 152 mM and 190 mM respectively in the final formulation. The 253 
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formulated Cpn10 was filtered through a 0.2 μm filter under aseptic conditions and 500ml 254 
(2.5 g Cpn10) dispensed into 500 mL pyrogen- free plastic bottles. 255 
 256 
Spectrophotometric and SDS-PAGE analysis of Cpn10 257 
SDS PAGE of E. coli cell lysates and chromatography fractions was performed using 258 
NuPAGE 4-12% Bis-Tris gradient gels (Invitrogen).  Gels were Coomassie Brilliant Blue 259 
stained and each gel included Cpn10 protein and molecular weight standards. Cpn10 260 
concentrations were determined by UV absorbance on a Cary 50 Bio UV 261 
Spectrophotometer (Varian) at 280 nm using an extinction coefficient of 0.41 (mg/mL)-1 262 
cm-1. 263 
 264 
Mass Spectrometry 265 
Mass spectrometry was performed at the University of Adelaide Proteomics Centre, 266 
Adelaide, Australia. Whole molecule masses were determined by direct injection into an 267 
API-100 mass spectrometer (Applied Biosystems). Alternatively samples were desalted 268 
prior to analysis by C8 reversed-phase HPLC using a 10-60% acetonitrile gradient in the 269 
presence of 0.1% trifluoroacetic acid (TFA).  Protein modifications were identified by a 270 
combination of peptide mapping and mass spectrometry.  Protein was digested with either 271 
Trypsin (Promega) or Endoproteinase LysC (Sigma-Aldrich). Digested samples were 272 
analysed with an acetonitrile gradient on a Waters Symmetry 300 C18 column on a 2695 273 
Separation module (Waters) under the control of Millennium software. UV peaks were 274 
manually collected and sent to the Adelaide Proteomics Centre for identification. 275 
 276 
Peptide masses were determined with a MALDI TOF/TOF mass spectrometer (Ultraflex II, 277 
Bruker Daltonic GmbH) operating in reflectron mode under the control of flexControl 278 
software. Mass spectra were analysed with flexAnalysis (Bruker Daltonic GmbH). Ions 279 
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were fragmented by laser-induced dissociation and the sequence was assigned using the 280 
“Rapid De Novo” module of BioTools (Bruker Daltonic GmbH). 281 
 282 
Host cell DNA and endotoxin quantification 283 
The concentration of E. coli DNA in purified Cpn10 preparations was determined by 284 
Glycotope Biotechnology (Heidelberg, Germany) using the Threshold Total DNA Assay 285 
according to the manufacturer’s instructions (Molecular Devices, CA, USA; Product No. 286 
R8022). A quantitative chromogenic Limulus amebocyte lysate (LAL) test (BioWhittaker, 287 
QCL-1000) was used to estimate the concentration of gram-negative bacterial endotoxin 288 
present in the final preparation of Cpn10.  Assays were performed according to the 289 
manufacturer’s instructions. 290 
 291 
Size Exclusion Chromatography 292 
Soluble oligomer content was determined by size exclusion chromatography using a 293 
Superdex 200 HR 10/30 (GE Biosciences) size exclusion column.  Samples were analysed 294 
by injecting 100 μL onto the column and separated by isocratic elution at a flow rate of 0.5 295 
mL/min using 50 mM Sodium Phosphate pH 7.0 + 150 mM NaCl as the elution buffer.  296 
The apparent molecular weight of eluting species was estimated by comparison of peak 297 
retention times with globular protein standards of a known molecular weight. 298 
 299 
Glutaraldehyde cross-linking of Cpn10 300 
An amount of 580 µg of human recombinant Cpn10 in PBS (pH 7.4) was incubated with 301 
0.01 % (w/w) glutaraldehyde (APS) in a total volume of 300 µL at 25 °C for 30 min.  302 
Reactions were quenched by the addition of 15 µL of 2 M Tris-HCl pH 8.0. An aliquot of  303 
the reaction mixture was analysed by size exclusion chromatography to separate the 304 
different oligomeric species   and the peak eluting at the same retention time as the non-305 
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cross-linked Cpn10 oligomer was collected in two 0.5 mL fractions and analysed by SDS-306 
PAGE with silver staining. 307 
 308 
Stability testing of purified and formulated Cpn10 309 
Cpn10 batches 1, 2 and 3 (Table I) were sterile filled under nitrogen in glass vials at ~75 310 
mg mL-1 in 50 mM Tris-HCl pH 7.6 and 150 mM NaCl. Aliquots were placed at 2-8 oC 311 
and -80 oC for a period of 3 years. The integrity of the samples was tested at day 0 and at 312 
every six months up to 3 years. Stability tests included size-exclusion chromatography for 313 
heptamer verification, SDS-PAGE for purity and degradation, an A280nm measurement for 314 
protein concentration, endotoxin analysis for sterility and a quantitative bioassay for 315 
activity.  The bioassay constitutes the ability of Cpn10 to work as a co-chaperone for 316 
GroEL (E. coli Cpn60) in the process of rhodanese refolding [19]. The refolding buffer 317 
was 20 mM MOPS-KOH pH 7.5, 100 mM KCl and 10 mM MgCl2; bovine mitochondrial 318 
rhodanese was purchased from Sigma.  319 
 320 
Detection of proinflammatory E. coli contaminants by HEK cell assays 321 
In order to detect trace levels of contaminants derived from bacterial host, a bioassay was 322 
developed based on Toll like receptor (TLR)-transfected HEK cells and a luciferase 323 
reporter system (i.e. pNifty2-Luc plasmid DNA, InvivoGen). HEK cells transfected with 324 
TLR2, TLR3, TLR4/MD2/CD14 and TLR9 were created for detection of TLR ligands 325 
(agonists) Lipotechoic acid (LTA), Polyriboinosinic Polyribocytidylic Acid Poly (I:C),  326 
Lipopolysaccharide (LPS) and bacterial CpG DNA (CpG).   327 
 328 
HEK-TLR4-pNifty2-Luc and HEK-TLR9-pNifty2-Luc assays - HEK293XL or 329 
HEK293XL/hTLR9 cells (InvivoGen) and 10 µg mL-1 Blasticidin were grown in 75 cm2 330 
flasks for 1 week after recovery from liquid nitrogen.  Cells were briefly washed with PBS 331 
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then removed from the flasks using Trypsin-EDTA (0.05%).  Cells were split 1:3 in 75 cm2 332 
flasks and cultured overnight. Cells were transfected in flasks with Genejuice (Novagen) as 333 
follows: HEK293XL/TLR4/pNifty2-Luc Assay – 5 µg TLR4 plasmid DNA, 5 µg MD2 334 
plasmid DNA, 5 µg CD14 plasmid DNA and 3 µg pNifty2-Luc plasmid DNA (all 335 
InvivoGen); HEK-TLR9-pNifty2-Luc - 3ug pNifty2-Luc plasmid DNA.  DNA was mixed 336 
with Genejuice and incubated overnight (37 °C and 5% CO2) with the cells.   337 
 338 
Cells were trypsinised from the flask and plated out into 24-well plates at 1x105 cells per 339 
well and left to incubate overnight.  LPS from Escherichia coli (Sigma L-6529) was 340 
dissolved in sterile distilled water and stored at 4 °C at 1 mg mL-1 in glass vials.  341 
Immediately before use vials were vigorously vortexed before dilutions were made for 342 
assays.  Human CpGB-ODN 2006 (InvivoGen) was reconstituted to 500 µM with water 343 
before dilutions were made for assays.  Cells were incubated with LPS 344 
(HEK293XL/TLR4/pNifty2-Luc), CpGB (HEK-TLR9-pNifty2-Luc), batches of Cpn10 or 345 
control buffers for 20 h.  Medium was removed from the wells, and the adherent cells were 346 
briefly washed, before being processed for the luciferase assay (Luciferase Assay System, 347 
Promega).  Luciferase activity was read for 10 seconds on a Wallac Victor 2 (Perkin Elmer) 348 
Luminometer.  349 
 350 
HEK-TLR2-pNifty2-Luc and HEK-TLR3-pNifty2-Luc assays - HEK-TLR2-pNifty2-Luc 351 
and HEK-TLR3-pNifty2-Luc cell lines were prepared in-house by stable transfections of 352 
HEK293XL cells with TLR2, TLR3 and pNifty2-Luc plasmids (InvivoGen).  These cells 353 
were grown in 75 cm2 flasks for 1 week after recovery from liquid nitrogen, in media 354 
containing 400 µg mL-1 Zeocin and 30 µg mL-1 Blasticidin.  Cells were trypsinised from 355 
flask(s) and plated out into 24-well plates at 1x105 cells per well and left to incubate 356 
overnight.  Lipotechoic Acid (LTA) 5 mg (InvivoGen) was dissolved in sterile distilled 357 
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water to 10 mg mL-1 and stored at 4 °C in vials. Immediately before use vials were 358 
vigorously vortexed before dilutions were made for assays.  359 
 360 
Poly (I:C) 10 mg (InvivoGen) was reconstituted to 2.5 mg mL-1 with water before dilutions 361 
were made for assays.  Cells were incubated with LTA (HEK-TLR2-pNifty2-Luc), Poly 362 
(I:C) (HEK-TLR3-pNifty2-Luc), batches of Cpn10 or control buffers for 20 h. Medium 363 
was removed from the wells, and the adherent cells were briefly washed, before being 364 
processed for the luciferase assay (Luciferase Assay System, Promega). Luciferase activity 365 
was read for 10 s on a Wallac Victor 2 (Perkin Elmer) Luminometer.  366 
 367 
Results and Discussion 368 
Production strain development 369 
Bioprocess development from the initial stages of protein expression through to generation 370 
of the final production strain incorporates a number of optimisation steps.  The strain used 371 
in early, small-scale bioprocess development may not be the optimal strain for large-scale 372 
production, for reasons that include suitability of media formulation, promoter system, 373 
levels of product variants and choice of selectable marker.  For example, codon 374 
optimisation is generally required to maximise expression and minimise the level of 375 
product variant(s) due to mistranslation at rare codons. 376 
 377 
In the early stages of bioprocess development Cpn10 production was performed in XL1-378 
Blue cells utilising a heat-inducible promoter system (pPL550:cpn10). The XL1-Blue 379 
expression system has been described previously in the literature [18 20] however, as will 380 
be shown, was found to be inadequate for large-scale production. Bioprocess optimisation 381 
ultimately resulted in the production of Cpn10 for Phase IIa clinical trials in strain BR067 382 
from an IPTG inducible tac promoter-based expression construct.  Figure 1 shows SDS-383 
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PAGE analyses of the soluble fraction from cell lysates throughout the bioprocess 384 
development. Cpn10 is a heptamer of molecular weight (Mr) 70 kDa, with the monomeric 385 
form visualised at Mr 10 kDa by SDS-PAGE.  Cpn10 yield (g L-1) in the optimised BR067 386 
strain fermentate increased around 8-9 fold and improved product purity from ~88% to 387 
97% compared to product made in the XL1-Blue strain (Table I).  Importantly, total 388 
product variants, as a percentage of purified Cpn10, were reduced from 12.1% in the XL1-389 
Blue system to 3.2% in the final BR067 production strain (Table IB).    390 
 391 
Although the XL1-Blue strain allowed production of sufficient quantities of Cpn10 for 392 
early stage product development, there were a number of drawbacks. The inadequacies 393 
included the requirement for complex media, use of β-lactam-based antibiotics which can 394 
potentially cause allergic reactions, the difficult to control heat shock inducible promoter at 395 
large fermentation volumes, inability to achieve high cell densities and generation of 396 
unacceptably high levels of mistranslation variants.  The removal of product variants was 397 
first attempted by total codon optimisation of the human Cpn10 cDNA for production in E. 398 
coli.  Surprisingly, total codon optimisation in the BR067 strain significantly reduced 399 
expression levels of Cpn10 (compare Fig.1A, lane 5 and Fig. 1B, lane 1); as a result partial 400 
codon optimisation was next attempted.   401 
 402 
Investigation of XL1-Blue derived Cpn10 variant profile by RP-HPLC revealed one major 403 
contaminating peak; subsequent mass spectrometry analysis identified a large amount of 404 
the production variant Cpn10-G39E and an additional variant where Cpn10 was acetylated 405 
on residue K40 (Fig. 1C). For this reason, partial codon optimisation first targeted the rare 406 
glycine codon encoding residue G39 in the human Cpn10 cDNA. Figure 1A shows that 407 
equivalent expression levels were obtained with the wild type (wt) Cpn10 cDNA and the 408 
G39 codon optimised (G39-opt) cDNA when produced from the XL1-Blue strain, but 409 
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more importantly, the Cpn10-G39E variant peak visible by RP-HPLC was significantly or 410 
completely removed (data not shown).   411 
 412 
Given the inability of XL1-Blue to achieve high cell densities (Table IA), expression of the 413 
wt and G-opt cDNAs from the heat-inducible promoter system (pPL550:cpn10) was next 414 
attempted in BR067 cells.  Again equivalent expression levels were obtained with the wt 415 
Cpn10 cDNA and the G39 codon optimised (G39-opt) cDNA when produced from BR067 416 
cells (Fig. 1A). However as expected, BR067 ferments typically reached a cell density of 417 
OD600nm  ~110 (data not shown) compared to XL1-Blue ferments which only reached a cell 418 
density of OD600nm  ~25 (Table IA). The increase in cell density achieved with the BR067, 419 
compared to the XL1-Blue, cell line was ~4.6 fold.  420 
 421 
The use of the G39 codon optimised Cpn10 cDNA in BR067 cells addressed numerous 422 
inadequacies of the original XL1-Blue strain for large-scale production, however, the 423 
issues of the undesirable β-lactam-based antibiotic selection marker and the difficult to 424 
control heat shock promoter still remained.  In order to address these concerns and 425 
maximise Cpn10 expression levels, a series of pBR322-based expression constructs 426 
harbouring a Kanamycin selection marker, ColE1 origin of replication and lac repressor 427 
gene (lacI) were screened.  428 
 429 
The expression constructs varied by their use of IPTG-inducible trc or tac promoter and 430 
transcriptional termination sequences. The best Cpn10 (G39-opt) expression was achieved 431 
with a combination of the IPTG-inducible tac promoter and the rrnBT1T2 transcription 432 
termination sequence in the BR067 cell line (Fig. 1B and data not shown). All subsequent 433 
work was completed in this production system.   434 
 435 
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The establishment of an optimal expression system and continual efforts to improve the 436 
RP-HPLC method, for detection and quantitation of Cpn10 production variants, uncovered 437 
yet additional inadequacies in the wt and partially codon optimised Cpn10 cDNA.  A 438 
combination of removal of Cpn10-G39E variant and optimisation of the RP-HPLC 439 
gradient, revealed the presence of small amounts (~1%) of new production variant Cpn10-440 
G39D (data not shown).  A decision was made to attempt to optimise all rare glycine 441 
codons within Cpn10 to prevent the unforeseen appearance of further trace amounts of 442 
glycine variants as the program progressed. Figure 1B shows that equivalent expression 443 
levels were obtained with the wt Cpn10 cDNA, the G39 codon optimised (G39-opt) cDNA 444 
and when all rare glycine codons were optimised (G-opt) in the Cpn10 cDNA. RP-HPLC 445 
analysis of Cpn10 from the all glycine codon optimised construct, revealed that while the 446 
major G39E + acetylated K40 peak had been minimised, two new additional peaks were 447 
present (Fig. 1C, G-opt).   448 
 449 
Mass spectrometry analysis identified these peaks as two stop codon (TGA) aberrant 450 
translational read-through variants.  Translational read-through at TGA termination codons 451 
has previously been documented during the overexpression of recombinant proteins [21] 452 
with read-through is a more common event at TGA than TAA termination codons [22].  At 453 
approximately the same time that the two stop codon read-through variants were identified, 454 
a shallow gradient RP-HPLC analysis of purified Cpn10, expressed from the wt cDNA in 455 
the original XL1-Blue system, revealed the presence of an additional Cpn10 variant where 456 
arginine residue 92 was substituted for a Lysine (i.e. R92K) according to mass 457 
spectrometry analysis. The Cpn10-R92K variant was present at ~8.1% of the total purified 458 
Cpn10 material (Table IB).  In prior RP-HPLC runs, utilising a steeper gradient, the 459 
Cpn10-R92K variant is hidden within the main Cpn10 peak (Fig. 1C).  A shallow gradient 460 
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analysis of the all glycine codon optimised construct, expressed from the BR067 cell line, 461 
also detected the presence of the Cpn10-R92K variant.   462 
 463 
A final codon optimised Cpn10 cDNA was designed where all glycine codons, all arginine 464 
codons and the stop codon (TGA to TAA) were optimised (GRstop-opt).  Figure 1B shows 465 
that equivalent expression levels were obtained with the wt cDNA, G39-opt cDNA, G-opt 466 
cDNA and the GRstop-opt cDNA in BR067 cells.  More importantly, RP-HPLC analysis 467 
revealed that the two stop codon read-through variants and the Cpn10-R92K variant were 468 
not detectable while the Cpn10-G39E and acetylated Cpn10-K40 were significantly 469 
minimised (Fig. 1C and D, Table IB).  470 
 471 
Cpn10 production in the BR067 strain, utilising the GRstop-opt cDNA and optimised 472 
pBR322 expression construct (hereafter termed BR067 production strain), showed optimal 473 
characteristics, including high cell density growth in defined media, suitable selection 474 
marker and high expression yields with minimal levels of product variants.  475 
  476 
Structure, function and stability 477 
Confirmation of heptameric structure  478 
Cpn10 is a heptamer, made up of seven identical monomers.  SDS-PAGE analysis of 479 
Cpn10 derived from BR067 production strain is shown in Figure 2A; an overloading of the 480 
gel with Cpn10 qualitatively shows >99% purity, with no other bands visible.  In order to 481 
confirm Cpn10’s heptameric structure, Cpn10 oligomers were partially cross-linked with 482 
glutaraldehyde.  Partial cross-linking of Cpn10 favoured intra-oligomer links to be formed 483 
(i.e. linkage of monomers within an oligomeric unit) and limited inter-oligomer cross-links 484 
(i.e. artificial linking of several oligomeric units).  485 
 486 
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Subsequent separation by size exclusion chromatography and collection of the material 487 
which eluted at the same position on the chromatogram as native Cpn10 oligomer, ensured 488 
that only intra-oligomer cross-linked species were isolated. SDS-PAGE analysis of this 489 
material revealed seven discrete protein bands, representing Cpn10 monomer and cross-490 
linked dimer, trimer etc. through to heptamer, indicating that Cpn10 adopts a heptameric 491 
structure that is characteristic of all Cpn10 members (Fig. 2B).  The apparent molecular 492 
weight of heptameric Cpn10 was determined to be 94 ± 3 kDa (Fig. 2C).  The expected 493 
theoretical molecular weight of heptameric Cpn10 was estimated at 76kDa using the 494 
ExPasy Protein Parameter analysis tool (SIB; Swiss Institute of Bioinformatics). The slight 495 
discrepancy in apparent molecular weight could be attributed to the expanded packing of 496 
the subunits within the Cpn10 heptamer resulting in an increased Stokes radius. 497 
 498 
Activity and stability of purified, recombinant Cpn10 499 
The biological activity of Cpn10 (over time) was investigated as a molecular co-chaperone 500 
in protein folding, and was used as an indicator for structural integrity.  Cpn10 (>99% pure) 501 
expressed in E. coli was formulated in 50 mM Tris-HCl (pH 7.6) and 150 mM NaCl.  502 
When stored at ~75 mg mL-1 and 2-8 oC for at least 3 years, Cpn10 retained full activity as 503 
a co-chaperone in the process of E. coli GroEL-mediated rhodanese refolding (Fig. 2D). 504 
The bioassay revealed that small differences in Cpn10 activity can be detected by varying 505 
the amount of Cpn10, illustrating its usefulness for ensuring the integrity of Cpn10 506 
production batches.  In agreement with the retention of full biological activity after 3 years 507 
stored at 2-8 oC, no significant changes to the product variant profile were observed by RP-508 
HPLC and no changes were observed to the heptameric structure by SEC (data not shown). 509 
Cpn10 is therefore a very stable protein, which is probably not unexpected given that it is a 510 
stress-inducible protein and fulfils an essential role in the maintenance of cellular 511 
homeostasis.  512 
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 513 
Methionine oxidation can have significant effects on the activity of a protein; for example, 514 
oxidation of the exposed, N-terminal-methionine of α-polypeptide in the light-harvesting 515 
complex from Rhodospirillum rubrum affects its ability to form the B820 subunit with β-516 
polypeptide and bacteriochlorophyll a [23]. Cpn10 contains a single Met residue at 517 
position 33 of the mobile loop (i.e. 32-Ile-Met-Leu-34), which is crucial for its efficient 518 
interaction with Cpn60.  Therefore, potential oxidation of this Met residue was investigated 519 
by mass spectrometry.  Tandem mass spectra of Cpn10 indicated the Met residue is readily 520 
oxidised by hypochlorite (data not shown), however only 0.5% of the purified Cpn10 521 
material was observed to be oxidized at the end of production (Table IB). More 522 
importantly, storage at ~75 mg mL-1 under nitrogen for 3 years at 2-8 oC resulted in <1.5 % 523 
product oxidation, indicating that oxidation will not be a concern for biological activity.   524 
 525 
Mass spectrometry  526 
The mass of purified Cpn10, determined by mass spectrometry was 10,872.2 ± 1 Da (data 527 
not shown), in agreement with the theoretical mass of 10,871.5 Da.  To confirm the 528 
primary sequence of Cpn10, a tryptic peptide map was developed and the 14 resulting 529 
peptides were identified by mass spectrometry (Fig. 3). The mass spectrometry-based 530 
identity of the peptides in peaks 1, 10, 13 and 14, was corroborated by their strong 531 
absorbance at A280nm as peptides containing tyrosine residues (data not shown).  Mass 532 
spectrometry was an invaluable tool for monitoring product integrity during process 533 
development and for tracking the level of product variants.  534 
 535 
Purified recombinant Cpn10 lacks proinflammatory E. coli contaminants 536 
The observed effects of recombinant heat shock protein preparations on the immune 537 
system have been quite controversial owing to the potential presence of pro-inflammatory 538 
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E. coli components that may alone be responsible for activity [24].  To illustrate that 539 
recombinant Cpn10 preparations lacked major E. coli pro-inflammatory contaminants, 540 
highly sensitive HEK reporter cell lines transfected with either TLR2, TLR3, 541 
TLR4/MD2/CD14 or TLR9 were used. Figure 4 shows that when TLR-transfected HEK 542 
cells were challenged with aliquots of Cpn10 from three separate GMP batches of BR067, 543 
readouts were below the level of detection for the appropriate ligand, indicating a robust 544 
downstream process that yields Cpn10 preparations that are essentially free of bacterially-545 
derived contaminants. 546 
 547 
GMP production of Cpn10 548 
Human Cpn10 was produced in the E. coli BR067 production strain in 100 L fed-batch 549 
fermentations performed under cGMP at Hospira, Adelaide, Australia.  Cpn10 protein was 550 
completely soluble and purified from the cellular lysate after disruption and clarification.  551 
Compared to XL1-Blue at the same fermentation scale, use of the BR067 strain resulted in 552 
an ~5 fold increase in cell density and an ~9- fold increase in expression levels which 553 
ultimately resulted in a near 6-fold increase in final product.  554 
 555 
Cpn10 was purified by a downstream process incorporating three sequential IEX 556 
chromatography steps; SP-BB, Q-FF and SP-HP chromatography (Table IA).  Throughout 557 
the downstream process, chromatographic fractions were analysed by RP-HPLC for purity 558 
and yield of Cpn10 (Table IA).  The average pI for E. coli host proteins is 5.7 [25]. As the 559 
pI of Cpn10 (8.91) is significantly greater than the majority of the E. coli proteins,  the 560 
downstream process resulted in a final SDS-PAGE purity of > 99%.   561 
 562 
SP-BB cation exchange capture facilitated concentration of the Cpn10 while the majority 563 
of host cell protein contaminants were removed in the flow-through.  SP-BB 564 
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chromatography resulted in a significant and variable loss of Cpn10 (44-83%), despite an 565 
excess of resin and conditions which should have facilitated binding of Cpn10.  Re-566 
application of the non-binding fraction, containing ~50% of the Cpn10, resulted in a 567 
modest recovery (~10%). Characterisation of this non-binding material by RP-HPLC and 568 
mass spectrometry indicated that it was identical to material retained on the SP-BB resin. 569 
An attempt to dissociate Cpn10 from an unknown bound entity using urea or organic 570 
alcohols improved binding to >90%, however led to the formation of an apparent Cpn10 571 
heptamer dimer (<20% of total Cpn10) (data not shown).  A decision was made to accept 572 
the lower Cpn10 recovery on SP-BB to achieve the maximum purity.  573 
 574 
Operation of Q-FF IEX chromatography at pH 8.0 ensured that the Cpn10 was contained 575 
in the flow-through, whilst residual host cell proteins, DNA and endotoxin bound to the 576 
column.  The SP-HP final polishing step resulted in the production of clinical grade Cpn10, 577 
with a purity >99% by SDS-PAGE.  Table IB shows the product variant profile for three 578 
cGMP Cpn10 batches and an average product variant level of 3.3%.  Table IB additionally 579 
shows numerous Cpn10 characterisation tests which ensure suitability for human 580 
administration.  Endotoxin (<0.6 EU mg-1), based on dosage levels, is well below the 581 
required limit of 5 EU kg-1 body weight per hr for an intravenous application of a 582 
therapeutic protein [26].   583 
 584 
GMP formulation of Cpn10 585 
Cpn10 bulk drug substance (BDS) was manufactured by Hospira, a GMP facility in 586 
Adelaide, South Australia.  Hospira has produced Cpn10 at a manufacturing scale (100L) 587 
to supply material for preclinical and clinical studies, preparation of a reference lot, and 588 
stability studies.  Cpn10 produced from the cell line XL-1Blue was manufactured for phase 589 
I and phase II clinical trials, Cpn10 produced from the BR067 process was manufactured 590 
Page 24 of 40
Ac
ce
pte
d M
an
us
cri
pt
 24
for GLP toxicology studies and phase II clinical trial material.  Cpn10 produced by both 591 
methods has demonstrated equivalent performance by biological, physicochemical and in 592 
vitro safety parameters.  The two features identified as different were the reduction in 593 
BR067 derived product of translational variants and the removal of an unidentified agonist, 594 
as detected by a macrophage reporter cell line, both being desirable improvements on the 595 
old process.   596 
 597 
The Sponsor transferred its bulk manufactured Ala-Cpn10 product to its GMP CMC 598 
partner, Gallus Biopharmaceuticals (Princeton, NJ), for formulation and release under 599 
GMP conditions in their Food and Drug Administration (FDA) approved facilities.  Gallus 600 
Biopharmaceuticals have since validated a suite of characterisation assays which have 601 
demonstrated suitability for the determination of purity and identity of Cpn10 prior to 602 
formulation and release of drug product according to defined, FDA approved, 603 
specifications.   604 
 605 
Conclusion  606 
A bioprocess for the production of ~115 g of clinical grade Cpn10 (representing an overall 607 
recovery of 26%)  from a 100 L E. coli fermentation was developed incorporating cation 608 
and anion exchange chromatography purification.  Cpn10 was characterised with respect to 609 
purity by SDS-PAGE (> 99%), identification of product variants (3.2%), in vitro biological 610 
activity and stability.  Key improvements to process productivity were achieved through 611 
changing the host production cell line, the choice of promoter and termination sequences 612 
and through partial codon optimisation. These changes resulted in elevated final cell 613 
density in the bioreactor, higher specific Cpn10 productivity and reduced the proportion of 614 
product variants, which was critical for the production of clinical-grade protein.    615 
Biochemical stability testing revealed no loss in chaperone activity and no significant 616 
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chemical change when stored at 75 mg mL-1 and 2-8 oC for at least 3 years.  The final 617 
bioprocess yields Cpn10 of high purity which lacks detectable levels of proinflammatory E. 618 
coli contaminants.  The bulk material produced by this process has been formulated and 619 
released in a GMP, FDA approved facility according to the acceptance specifications for 620 
validated characterisation assays for purity, identity and potency.  Ala-Cpn10 is currently 621 
being trialled under a US IND116156 in a blinded, placebo-controlled phase II clinical 622 
study in patients with SLE .   623 
 624 
 625 
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Table and Figure Legends 703 
 704 
Table I  705 
Comparison of Cpn10 attributes during optimisation of production. 706 
A 707 
Upstream data for production of Cpn10 in host strains XL1-Blue and BR067, and 708 
downstream processing unit operations for purification of Cpn10 from BR067 production 709 
strain cell lysate, including Cpn10 purity and recovery for each unit operation.   710 
 711 
B 712 
Process contaminant levels and product variant profile for Cpn10 produced in host strains 713 
XL1-Blue and BR067; other impurities include low levels of des (1-7) Cpn10; release 714 
testing; includes assays for Cpn10 concentration by absorbance at 280 nm (A280nm); 715 
purity by SDS-PAGE; aggregation by size exclusion chromatography (SEC); chaperonin 716 
activity as an indication of biological activity and analysis of process related impurities, i.e. 717 
host cell DNA and endotoxin  718 
# The limit of quantitation for the RP-HPLC method was 2% while the level of detection 719 
was ~1%. 720 
* The limit of quantitation for the Threshold Total DNA assay was 18 pg of DNA per mg 721 
of Cpn10 while the level of detection was 6 pg/mg.   722 
 723 
724 
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Figure 1,   724 
 725 
Analysis of Cpn10 expression levels and variant profiles when produced in E. coli. 726 
 727 
A and B,  SDS-PAGE analysis of clarified host strain lysates expressing Cpn10 from the 728 
wild-type (wt) cDNA and numerous codon optimised cDNAs.  The band corresponding to 729 
Cpn10 is shown (Mr 10 kDa). 730 
A   731 
Strains XL1-Blue and BR067 with pPL5550 heat inducible promoter based Cpn10 732 
expression constructs. 733 
B   734 
BR067 strain with pBR322, IPTG inducible tac promoter based Cpn10 expression 735 
constructs. 736 
C and D   737 
Cpn10 purified from numerous expression constructs (indicated in panels A and B) was 738 
analysed by RP-HPLC to reveal levels of Cpn10 production variants.  The constructs tested 739 
were XL1-Blue cells expressing Cpn10 from the wt cDNA (Panel A, lane 3) and BR067 740 
cells expressing Cpn10 from an all Glycine-codons optimised cDNA (G-opt; Panel B, lane 741 
3) and an all Glycine, Arginine and stop-codon optimised cDNA (GRstop-opt; Panel B, 742 
lane 4). 743 
C. RP-HPLC analysis of purified Cpn10 using a 25-45% acetonitrile gradient over 40 min. 744 
Peak G39E + acetylated K40 indicates co-elution of these Cpn10 variants; stop-1 and stop-745 
2 indicate two stop-codon read-through Cpn10 variants.   746 
D  747 
RP-HPLC analysis of purified Cpn10 using a shallow 30-32% acetonitrile gradient over 748 
40min.  The extended gradient revealed an arginine 92 to lysine (R92K) product variant in 749 
XL1-Blue derived material, produced from the wt Cpn10 cDNA.  The Cpn10 production 750 
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variants detected by RP-HPLC in panels C and D were undetectable or significantly 751 
reduced in GRstop-opt (i.e. BR067 production strain).  In panels C and D the main Cpn10 752 
peak is indicated with an asterisk.  753 
 754 
Figure 2 755 
Characterisation of purified Cpn10. 756 
A,  757 
SDS-PAGE analysis of purified Cpn10. Varying amounts of purified Cpn10 were loaded 758 
into adjacent lanes. Relative percentages (%) are indicated to illustrate a purity of >99%.   759 
B,  760 
Glutaraldehyde cross-linking of human recombinant Cpn10.  Silver stained 4-20% SDS-761 
PAGE analysis of partially cross-linked Cpn10 oligomers reveals seven distinct species 762 
confirming a heptameric structure. Lane 1, molecular weight standards; Lane 2, cross-763 
linked Cpn10; Lane 3, is a lighter exposure of lane 2 for better clarity of bands 5, 6 and 7.  764 
C,  765 
Size exclusion chromatograms (Superdex-200 HR 10/30) of Cpn10.  Cpn10 is a heptamer 766 
of identical subunits, and elutes with an apparent Mr of 94 ± 3 kDa.  Cpn10 (cross-linked) 767 
is predominantly a heptamer containing intra-oligomer cross-links eluting with an apparent 768 
Mr of 93 ± 3 kDa, and some higher oligomers containing inter-oligomer cross-links.  The 769 
molecular weight (MW) standards were thyroglobulin 669 kDa, catalase 232 kDa, albumin 770 
67 kDa and chymotrypsinogen A 25 kDa. 771 
 772 
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 773 
 774 
D,   775 
Cpn10 is active as a molecular  co-chaperone during the GroEL-dependent folding of 776 
denatured rhodanese.  Rhodanese was denatured in 6M guanidine-HCl and diluted 100-777 
fold (final concentration 400 nM) in the presence (∇, ▼, □, ■) or absence (o) of 500 nM 778 
GroEL (ie spontaneous folding). Varying amounts of Cpn10 were added (as indicated) and 779 
rhodanese refolding was initiated with 5mM ATP.  At the times indicated, GroEL action 780 
was stopped with 50 mM EDTA and rhodanese activity was measured. 781 
 782 
Figure 3,    783 
The identity of Cpn10 was confirmed with a tryptic peptide map resolved by RP-HPLC (A) 784 
and analysed by mass spectrometry (B) Peptide peaks 1, 10, 13 and 14 (marked with an 785 
asterisk) absorbed strongly at 280nm due to the presence of tyrosine residues. 786 
 787 
Figure 4,   788 
Lack of E. coli proinflammatory contaminants in preparations of recombinant Cpn10.  789 
HEK cells transfected with TLR2 (panel A), TLR3 (panel B), TLR4/MD2/CD14 (panel C) 790 
and TLR9 (panel D) were stimulated for 20 hr with a range of the appropriate ligand, three 791 
Cpn10 batches and the Tris buffer used to formulate Cpn10.  The limit of detection for 792 
each assay is mark with an asterisk. Data represents the mean of triplicate wells ± S.D. 793 
LTA, Lipotechoic acid; Poly (I:C), Polyriboinosinic Polyribocytidylic Acid; LPS, 794 
Lipopolysaccharide; CpG ODN 2006,  unmethylated oligonucleotide 2006 (human type B) 795 
containing CpG motifs. 796 
 797 
 798 
Page 34 of 40
Ac
ce
pte
d M
an
us
cri
pt
 34
 799 
Table I  800 
 801 
 802 
 803 
 804 
 805 
 806 
 807 
 808 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
 820 
 821 
 822 
 823 
 824 
 825 
826 
Upstream - Fermentations 
 
Volume 
Processed 
(L) 
 
Cpn10 
Amount 
(g) 
 
Cpn10 
Conc 
(g/L) 
 
Cell 
Density 
(OD600nm) 
 
Final  
Yield 
(g) 
XL1-Blue expression strain (n=3) 
   (wt Cpn10 in pPL550) 97 ± 3 64.1± 12.1 0.7 ± 0.1 25.5 ± 0.2 19.8 ± 4.8 
BR067 production strain (n=3) 
   (GRstop-opt  Cpn10) 71 ± 2 442.1 ± 76.3 6.2 ± 0.9 126 ± 12 115.0 ± 9.3 
Downstream processing  
(unit operations)  – 
BR067 production strain 
Volume (L) 
     Cpn10 
Amount 
(g) 
    Cpn10 
Conc. 
(g/L) 
    Cpn10 
Purity 
(%) 
      Step 
Recoveries 
(%) 
Lysate post filtration 95 529.2 5.57 ND ND 
SP-BB Eluate 14 249.8 17.84 ND 47.2 
Diafiltered SP-BB 12.9 188.4 14.64 ND 75.4 
Q-FF Eluate 22.6 162.4 7.20 >99 86.2 
SP-HP Eluate 11.9 110.7 9.30 >99 68.3 
Formulated Cpn10 21.8 111.9 5.14 >99 100 
Filtered Drug Substance 21.7 111.4 5.14 >99 100 
Cpn10 & Variant Profile 
(analysed by RP-HPLC#) 
wt 
n=1 
GRstop-opt 
n=3 
Cpn10 
G39E / Acetylated K40 
R92K 
87.9 
3.6 
8.1 
96.8 ± 0.5 
0.7 ± 0.1 
0.0 ± 0.0 
G39D 0.0 1.9 ± 0.1 
Oxidised M31 0.0 0.4 ± 0.0 
Other impurities 0.4 0.2 ± 0.1 
Total Impurities 12.1 3.2 ± 0.5 
Characterisation 
Test 
wt 
n=3 
GRstop-opt 
n=3 
A280nm Cpn10 (g L-1) 5.06 ± 0.06 5.09 ± 0.14 
Purity by SDS-PAGE (%) > 99 > 99 
SEC (%) 99.6 ± 0.2 99.0 ± 0.4 
  Host cell DNA (pg/mg*) 4.6 ± 5.0 6.0 ± 1.7 
Endotoxin   (EU mg-1) < 0.4 ± 0.5 < 0.6 ± 0.4 
Chaperone Activity 
(% of control) 107.7 ± 4.2 102.0 ± 2.4 
A 
B 
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 826 
Figure 1  827 
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 843 
844 
C D
A B
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 844 
Figure 2 845 
 846 
 847 
848 
C A 
B D 
14.4 
20 
30 
45 
66 
97 
kDa 
44.8 1.3 0.45 µg 
100 2.9 1.0 % 
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 848 
Figure 3 849 
 850 
 851 
 852 
 853 
 854 
 855 
 856 
 857 
 858 
 859 
 860 
 861 
 862 
 863 
 864 
 865 
 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
 886 
 887 
 888 
 889 
 890 
 891 
 892 
 893 
894 
Peak 
No. 
RT 
(min) 
Observed 
Ion masses 
 (singly charged) 
Probable Identity 
of tryptic peptide 
Predicted 
Ion masses 
1 13 396.27 100YVD102 396.18 
2 16 806.41 21SAAETVTK28 806.43 
3 19 
 
848.47 
720.37 
1AAGQAFRK8 
1AAGQAFR7 
848.47 
720.38 
4 19.5 720.37 
848.47 
1AAGQAFR7 
1AAGQAFRK8 
720.38 
848.47 
5 21 615.16 16VLVER20 615.38 
6 23.5 717.36 93DGDILGK99 717.38 
7 24 1198.70 55GKGGEIQPVSVK66 1198.68 
8 24.5 1198.68 
1013.56 
55GKGGEIQPVSVK66 
57GGEIQPVSVK66 
1198.68 
1013.56 
9 30 1315.76 41VLQATVVAVGSGSK54 1315.76 
10 32 1076.62 71VLLPEYGGTK80 1076.60 
11 46 1035.61 8KFLPLFDR15 1035.60 
12 47 907.51 
1529.80 
9FLPLFDR15 
81VVLDDKDYFLFR92 
907.50 
1529.80 
13 47.5 1529.81 81VVLDDKDYFLFR92 1529.80 
14 49 2228.18 81VVLDDKDYFLFRDGDILGK99 2228.16 
A 
B 
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Figure 4 894 
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Highlights 
1. Production of a novel protein based therapeutic for treating inflammatory diseases.  
2. Process productivity improved using specific host strain and gene promoter elements.  
3. Partial codon optimisation of Cpn10 gene reduced molecular variants  
 
 
 
*Highlights (for review)
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